ZA200600126B - Piperazine derivatives and their use as therapeutic agents - Google Patents
Piperazine derivatives and their use as therapeutic agents Download PDFInfo
- Publication number
- ZA200600126B ZA200600126B ZA200600126A ZA200600126A ZA200600126B ZA 200600126 B ZA200600126 B ZA 200600126B ZA 200600126 A ZA200600126 A ZA 200600126A ZA 200600126 A ZA200600126 A ZA 200600126A ZA 200600126 B ZA200600126 B ZA 200600126B
- Authority
- ZA
- South Africa
- Prior art keywords
- hydrogen
- independently selected
- group
- compound
- rings
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 8
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title description 4
- 150000004885 piperazines Chemical class 0.000 title description 3
- 229940124597 therapeutic agent Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- -1 R 10a Chemical compound 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 241000124008 Mammalia Species 0.000 claims abstract description 11
- 230000001404 mediated effect Effects 0.000 claims abstract description 11
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 109
- 239000001257 hydrogen Substances 0.000 claims description 109
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 75
- 108010087894 Fatty acid desaturases Proteins 0.000 claims description 40
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 150000002431 hydrogen Chemical class 0.000 claims description 33
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 125000001153 fluoro group Chemical group F* 0.000 claims description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 16
- 125000004043 oxo group Chemical group O=* 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
- 102000055981 human SCD1 Human genes 0.000 claims description 6
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 claims 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 3
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- IMLAIXAZMVDRGA-UHFFFAOYSA-N 2-phenoxyethanamine Chemical compound NCCOC1=CC=CC=C1 IMLAIXAZMVDRGA-UHFFFAOYSA-N 0.000 claims 1
- IIFDQESZTDBKEM-UHFFFAOYSA-N 3-(4-fluorophenyl)propan-1-amine Chemical compound NCCCC1=CC=C(F)C=C1 IIFDQESZTDBKEM-UHFFFAOYSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 claims 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims 1
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- FGOUAQGATIHMQX-UHFFFAOYSA-N n-(2-phenylethyl)-5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2C=NC(=NC=2)C(=O)NCCC=2C=CC=CC=2)CC1 FGOUAQGATIHMQX-UHFFFAOYSA-N 0.000 claims 1
- PNQGAOSCJVLAFG-UHFFFAOYSA-N n-benzyl-5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2C=NC(=NC=2)C(=O)NCC=2C=CC=CC=2)CC1 PNQGAOSCJVLAFG-UHFFFAOYSA-N 0.000 claims 1
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 abstract description 32
- 239000000194 fatty acid Substances 0.000 description 10
- 101100041816 Homo sapiens SCD gene Proteins 0.000 description 9
- 101150097713 SCD1 gene Proteins 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 5
- HPSSZFFAYWBIPY-UHFFFAOYSA-N malvalic acid Chemical compound CCCCCCCCC1=C(CCCCCCC(O)=O)C1 HPSSZFFAYWBIPY-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical class CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- PQRKPYLNZGDCFH-UHFFFAOYSA-N Sterculic-saeure Natural products CCCCCCCCC1=C(CCCCCCCC(O)=O)C1 PQRKPYLNZGDCFH-UHFFFAOYSA-N 0.000 description 3
- NMAKJOWVEDTHOA-UHFFFAOYSA-N 4-(chloromethyl)-1,3-thiazol-2-amine;hydron;chloride Chemical compound Cl.NC1=NC(CCl)=CS1 NMAKJOWVEDTHOA-UHFFFAOYSA-N 0.000 description 2
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940108924 conjugated linoleic acid Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- IYDVFMFKIKZKEK-UHFFFAOYSA-N 8-nonylsulfanyloctanoic acid Chemical compound CCCCCCCCCSCCCCCCCC(O)=O IYDVFMFKIKZKEK-UHFFFAOYSA-N 0.000 description 1
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 description 1
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 1
- 108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 description 1
- 102000009114 Fatty acid desaturases Human genes 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100309604 Homo sapiens SCD5 gene Proteins 0.000 description 1
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 101150048395 SCD gene Proteins 0.000 description 1
- 101100101423 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBI4 gene Proteins 0.000 description 1
- 101150042597 Scd2 gene Proteins 0.000 description 1
- 102100033930 Stearoyl-CoA desaturase 5 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- XDUHQPOXLUAVEE-BPMMELMSSA-N oleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 XDUHQPOXLUAVEE-BPMMELMSSA-N 0.000 description 1
- QBYOCCWNZAOZTL-MDMKAECGSA-N palmitoleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QBYOCCWNZAOZTL-MDMKAECGSA-N 0.000 description 1
- MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical group 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49109503P | 2003-07-30 | 2003-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200600126B true ZA200600126B (en) | 2007-04-25 |
Family
ID=34115467
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200600126A ZA200600126B (en) | 2003-07-30 | 2006-01-05 | Piperazine derivatives and their use as therapeutic agents |
| ZA200600125A ZA200600125B (en) | 2003-07-30 | 2006-01-05 | Pyridazine derivatives and their use as therapeutic agents |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200600125A ZA200600125B (en) | 2003-07-30 | 2006-01-05 | Pyridazine derivatives and their use as therapeutic agents |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7456180B2 (pl) |
| EP (2) | EP2316828A1 (pl) |
| JP (1) | JP4838128B2 (pl) |
| KR (1) | KR20060037409A (pl) |
| CN (3) | CN101693697A (pl) |
| AT (1) | ATE532772T1 (pl) |
| AU (2) | AU2004261268B2 (pl) |
| BR (1) | BRPI0412348A (pl) |
| CA (1) | CA2533901A1 (pl) |
| EC (1) | ECSP066311A (pl) |
| ES (1) | ES2377406T3 (pl) |
| IL (1) | IL173396A0 (pl) |
| MA (1) | MA28010A1 (pl) |
| NO (1) | NO20060971L (pl) |
| PL (1) | PL1651620T3 (pl) |
| PT (1) | PT1651620E (pl) |
| RU (1) | RU2006105717A (pl) |
| SG (1) | SG145701A1 (pl) |
| SI (1) | SI1648874T1 (pl) |
| TN (1) | TNSN06033A1 (pl) |
| WO (1) | WO2005011657A2 (pl) |
| ZA (2) | ZA200600126B (pl) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7494999B2 (en) | 2004-10-29 | 2009-02-24 | Kalypsys, Inc | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
| US7517884B2 (en) | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
| DK1311269T3 (da) | 2000-08-04 | 2012-03-26 | Dmi Biosciences Inc | Fremgangsmåde til anvendelse af diketopiperaziner og sammensætning, som indeholder dem |
| ES2572975T3 (es) | 2003-05-15 | 2016-06-03 | Ampio Pharmaceuticals, Inc. | Tratamiento de enfermedades mediadas por los linfocitos T |
| DE602004021206D1 (de) * | 2003-07-24 | 2009-07-02 | Euro Celtique Sa | Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen |
| US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| TWI345974B (en) | 2003-07-30 | 2011-08-01 | Xenon Pharmaceuticals Inc | Pyridazine derivatives and their use in the inhibition of stearoyl-coa desaturase |
| US7754711B2 (en) * | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| EP1651606B1 (en) * | 2003-07-30 | 2012-10-24 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
| AR051093A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa |
| US7547698B2 (en) | 2004-09-20 | 2009-06-16 | Xenon Pharmaceuticals Inc. | Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD) |
| EP1830837B1 (en) | 2004-09-20 | 2013-09-04 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| CN101090724A (zh) * | 2004-09-20 | 2007-12-19 | 泽农医药公司 | 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物 |
| JP5149009B2 (ja) * | 2004-09-20 | 2013-02-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体 |
| AU2005286728A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| AR051090A1 (es) * | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| MX2007003332A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
| MX2007003325A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa. |
| EP1866314B1 (en) * | 2005-02-16 | 2010-09-15 | NeuroSearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| MY158766A (en) | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| WO2006125181A2 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their use as stearoyl-coa desaturase modulators |
| WO2006125194A2 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2006125178A2 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic pyridazine compounds and their uses as therapeutic agents |
| WO2006125179A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
| WO2006125180A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2007046867A2 (en) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
| WO2007044085A2 (en) * | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| EP2029138A1 (en) | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| WO2007051095A1 (en) | 2005-10-25 | 2007-05-03 | Kalypsys, Inc. | Salts of modulators of ppar and methods of treating metabolic disorders |
| JP2009515839A (ja) * | 2005-11-15 | 2009-04-16 | メルク フロスト カナダ リミテツド | ステアロイル−ＣｏＡデルタ−９デサチュラーゼ阻害剤としてのアザシクロヘキサン誘導体 |
| WO2007071023A1 (en) * | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JP2009526059A (ja) | 2006-02-07 | 2009-07-16 | ワイス | １１−ベータｈｓｄ１阻害剤 |
| PT2029572E (pt) | 2006-06-05 | 2011-02-09 | Novartis Ag | Compostos orgânicos |
| WO2008003753A1 (en) * | 2006-07-07 | 2008-01-10 | Biovitrum Ab (Publ) | Pyrazolo [1,5-a] pyrimidine analogs for use as inhibitors of stearoyl-coa desaturase (scd) activity |
| CN101506203B (zh) | 2006-08-24 | 2013-10-16 | 诺瓦提斯公司 | 治疗代谢病、心血管病和其他病症的作为硬脂酰辅酶a脱饱和酶(scd)抑制剂的2-(吡嗪-2-基)-噻唑和2-(1h-吡唑-3-基)-噻唑衍生物及相关化合物 |
| JP2010505881A (ja) * | 2006-10-05 | 2010-02-25 | ギリアード・パロ・アルト・インコーポレイテッド | ステアロイルＣｏＡデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物 |
| ATE545416T1 (de) | 2006-10-12 | 2012-03-15 | Xenon Pharmaceuticals Inc | Verwendung von spiro-oxindol-verbindungen als therapeutika |
| US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| AR064965A1 (es) * | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
| US8575167B2 (en) | 2007-02-06 | 2013-11-05 | Takeda Pharmaceutical Company Limited | Spiro compounds having stearoyl-CoA desaturase action |
| JP2008239616A (ja) * | 2007-02-28 | 2008-10-09 | Iyaku Bunshi Sekkei Kenkyusho:Kk | Ｈｄｌ上昇剤 |
| EP2137187A1 (en) * | 2007-03-28 | 2009-12-30 | Inovacia AB | Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase |
| WO2008120759A1 (ja) * | 2007-03-30 | 2008-10-09 | Japan Tobacco Inc. | ウレア化合物およびその用途 |
| ES2571533T3 (es) * | 2007-04-27 | 2016-05-25 | Purdue Pharma Lp | Antagonistas de TRPV1 y usos de los mismos |
| WO2008143914A1 (en) | 2007-05-16 | 2008-11-27 | The University Of Maryland, College Park | Novel methods for recovery of leaf proteins |
| WO2008157844A1 (en) * | 2007-06-21 | 2008-12-24 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
| GB0715055D0 (en) * | 2007-08-02 | 2007-09-12 | Smithkline Beecham Corp | Compounds |
| ES2352098T3 (es) | 2007-08-08 | 2011-02-15 | Graceway Pharmaceuticals, Llc | Derivado de fenoxi-pirrolidina y su uso y composiciones. |
| BRPI0817211A2 (pt) * | 2007-09-20 | 2017-05-16 | Irm Llc | composto composições como moduladores da atividade de gpr119 |
| WO2009037542A2 (en) | 2007-09-20 | 2009-03-26 | Glenmark Pharmaceuticals, S.A. | Spirocyclic compounds as stearoyl coa desaturase inhibitors |
| GB0722077D0 (en) | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| EP2307023A4 (en) * | 2008-03-20 | 2011-07-20 | Forest Lab Holdings Ltd | NEW PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL COA DESATURASE |
| WO2009146320A1 (en) | 2008-05-27 | 2009-12-03 | Dmi Life Sciences, Inc. | Therapeutic methods and compounds |
| HRP20150882T1 (hr) | 2008-10-17 | 2015-09-25 | Xenon Pharmaceuticals Inc. | Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva |
| WO2010045197A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2010075356A1 (en) * | 2008-12-23 | 2010-07-01 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
| AU2010215035B2 (en) | 2009-02-17 | 2014-06-12 | Merck Canada Inc. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| GB0907425D0 (en) * | 2009-04-29 | 2009-06-10 | Glaxo Group Ltd | Compounds |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| WO2011011872A1 (en) | 2009-07-28 | 2011-02-03 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2011030139A1 (en) | 2009-09-11 | 2011-03-17 | Astrazeneca Ab | 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators |
| MY165579A (en) | 2009-10-14 | 2018-04-05 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| JP2013521232A (ja) | 2010-02-26 | 2013-06-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 局所投与のためのスピロオキシインドール化合物の医薬組成物および治療剤としてのその使用 |
| US8507496B2 (en) | 2010-09-07 | 2013-08-13 | Dmi Acquisition Corp. | Treatment of diseases |
| ES2620528T3 (es) | 2011-06-22 | 2017-06-28 | Purdue Pharma Lp | Antagonistas de TRPV1 que incluyen un sustituyente dihidroxi y usos de los mismos |
| BR112014007675A2 (pt) | 2011-10-10 | 2017-04-18 | Ampio Pharmaceuticals Inc | tratamento de doença articular degenerativa |
| BR112014007657A2 (pt) | 2011-10-10 | 2017-04-11 | Ampio Pharmaceuticals Inc | dispositivos médicos implantáveis com tolerância imune aperfeiçoada e métodos para produção e implantação |
| WO2013063413A1 (en) | 2011-10-28 | 2013-05-02 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
| US9233102B2 (en) | 2012-03-07 | 2016-01-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| EP2852387A2 (en) | 2012-05-22 | 2015-04-01 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Selective inhibitors of undifferentiated cells |
| US9808454B2 (en) | 2013-03-15 | 2017-11-07 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
| EP3105216B1 (en) | 2014-02-14 | 2018-10-10 | Takeda Pharmaceutical Company Limited | Pyrazine modulators of gpr6 |
| EP3808349B1 (en) | 2014-08-07 | 2022-10-05 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| EP3183240A4 (en) | 2014-08-18 | 2018-06-27 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| HK1246669A1 (zh) | 2015-06-22 | 2018-09-14 | Ampio Pharmaceuticals, Inc. | 人血清白蛋白低分子量组分在疾病治疗中的应用 |
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| AU2018205275B2 (en) | 2017-01-06 | 2024-05-02 | Janssen Pharmaceutica Nv | Methods for the treatment of neurological disorders |
| US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| AU2019238326B2 (en) | 2018-03-23 | 2025-03-06 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| CN108570039B (zh) * | 2018-04-25 | 2022-09-23 | 上海美迪西生物医药股份有限公司 | 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用 |
| KR20220007845A (ko) | 2019-01-24 | 2022-01-19 | 유마니티 테라퓨틱스, 인크. | 화합물 및 이의 용도 |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| EP4069367B1 (en) | 2019-12-06 | 2024-05-15 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| CN115772127B (zh) * | 2023-01-31 | 2023-05-16 | 山东佰隆医药有限公司 | 一种合成2-氰基-5-溴嘧啶的方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA983493A (en) * | 1972-10-11 | 1976-02-10 | Gilbert Regnier | Procede de preparation des derives du benzodioxole |
| DE2341925A1 (de) * | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| US4423049A (en) * | 1981-12-28 | 1983-12-27 | Mead Johnson & Company | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines |
| JPS6143173A (ja) * | 1984-08-06 | 1986-03-01 | Mitsui Petrochem Ind Ltd | 新規ピリミジン誘導体およびその製法 |
| JPS6187672A (ja) * | 1984-10-08 | 1986-05-06 | Mitsui Petrochem Ind Ltd | 新規ピリミジン誘導体 |
| US4734418A (en) * | 1984-12-14 | 1988-03-29 | Mitsui Petrochemical Industries, Ltd. | Quinazoline compounds and antihypertensives |
| JPS61238784A (ja) * | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | コハク酸イミド誘導体及びその酸付加塩 |
| WO1987004928A1 (fr) * | 1986-02-24 | 1987-08-27 | Mitsui Petrochemical Industries, Ltd. | Agents therapeutiques de la neuropathie |
| US5681956A (en) * | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
| FR2701260B1 (fr) * | 1993-02-05 | 1995-05-05 | Esteve Labor Dr | Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments. |
| CN1088062C (zh) * | 1994-11-23 | 2002-07-24 | 纽罗根公司 | 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体 |
| US6288230B1 (en) * | 1998-09-29 | 2001-09-11 | Neurogen Corporation | 2-(2, 3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands |
| ATE475718T1 (de) * | 2000-02-24 | 2010-08-15 | Xenon Pharmaceuticals Inc | Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika |
| GB0013383D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| DE60130771T2 (de) * | 2000-07-27 | 2008-07-17 | Eli Lilly And Co., Indianapolis | Substituierte heterocyclische amide |
| CA2430987A1 (en) | 2000-09-26 | 2002-04-04 | Xenon Genetics, Inc. | Methods and compositions employing a novel stearoyl-coa desaturase-hscd5 |
| EP1452525A4 (en) * | 2001-10-30 | 2005-01-26 | Nippon Shinyaku Co Ltd | AMIDE DERIVATIVES AND CORRESPONDING MEDICAMENTS |
| EP1456175A1 (en) * | 2001-12-07 | 2004-09-15 | Eli Lilly And Company | Substituted heterocyclic carboxamides with antithrombotic activity |
| AU2003202115A1 (en) * | 2002-02-12 | 2003-09-04 | Pfizer Inc. | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh) |
| CN1305850C (zh) | 2002-03-13 | 2007-03-21 | 詹森药业有限公司 | 作为组蛋白脱乙酰酶新颖抑制剂的磺酰基氨基衍生物 |
| EA006707B1 (ru) * | 2002-03-13 | 2006-02-24 | Янссен Фармацевтика Н. В. | Сульфонилпроизводные в качестве новых ингибиторов гистон-деацетилазы |
| OA12790A (en) | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | New inhibitors of histone deacetylase. |
| MXPA04010555A (es) * | 2002-04-25 | 2005-02-17 | Pharmacia Corp | Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa. |
| GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| MXPA05009661A (es) * | 2003-03-12 | 2006-03-08 | Kudos Pharm Ltd | Derivados de ftalazinona. |
| TWI345974B (en) | 2003-07-30 | 2011-08-01 | Xenon Pharmaceuticals Inc | Pyridazine derivatives and their use in the inhibition of stearoyl-coa desaturase |
-
2004
- 2004-07-29 CN CN200910207686A patent/CN101693697A/zh active Pending
- 2004-07-29 SG SG200805680-6A patent/SG145701A1/en unknown
- 2004-07-29 RU RU2006105717/04A patent/RU2006105717A/ru not_active Application Discontinuation
- 2004-07-29 WO PCT/US2004/024658 patent/WO2005011657A2/en not_active Ceased
- 2004-07-29 PT PT04779656T patent/PT1651620E/pt unknown
- 2004-07-29 BR BRPI0412348-4A patent/BRPI0412348A/pt not_active IP Right Cessation
- 2004-07-29 AU AU2004261268A patent/AU2004261268B2/en not_active Ceased
- 2004-07-29 PL PL04779656T patent/PL1651620T3/pl unknown
- 2004-07-29 CN CNA2004800219422A patent/CN1829701A/zh active Pending
- 2004-07-29 CA CA002533901A patent/CA2533901A1/en not_active Abandoned
- 2004-07-29 ES ES04779656T patent/ES2377406T3/es not_active Expired - Lifetime
- 2004-07-29 KR KR1020067002003A patent/KR20060037409A/ko not_active Ceased
- 2004-07-29 EP EP10184745A patent/EP2316828A1/en not_active Withdrawn
- 2004-07-29 AT AT04779656T patent/ATE532772T1/de active
- 2004-07-29 EP EP04779656A patent/EP1651620B1/en not_active Expired - Lifetime
- 2004-07-29 SI SI200431805T patent/SI1648874T1/sl unknown
- 2004-07-29 JP JP2006522096A patent/JP4838128B2/ja not_active Expired - Fee Related
- 2004-07-29 CN CNB200480021867XA patent/CN100558713C/zh not_active Expired - Fee Related
- 2004-07-29 US US10/567,009 patent/US7456180B2/en not_active Expired - Fee Related
-
2006
- 2006-01-05 ZA ZA200600126A patent/ZA200600126B/en unknown
- 2006-01-05 ZA ZA200600125A patent/ZA200600125B/en unknown
- 2006-01-25 EC EC2006006311A patent/ECSP066311A/es unknown
- 2006-01-26 IL IL173396A patent/IL173396A0/en unknown
- 2006-01-27 TN TNP2006000033A patent/TNSN06033A1/en unknown
- 2006-02-27 MA MA28838A patent/MA28010A1/fr unknown
- 2006-02-28 NO NO20060971A patent/NO20060971L/no not_active Application Discontinuation
-
2008
- 2008-10-08 US US12/247,792 patent/US8030488B2/en not_active Expired - Fee Related
-
2009
- 2009-06-11 AU AU2009202338A patent/AU2009202338A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200600126B (en) | Piperazine derivatives and their use as therapeutic agents | |
| JP4884219B2 (ja) | ピリジル誘導体および治療剤としてのその用途 | |
| US7829712B2 (en) | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase | |
| EP1763350B1 (en) | Nicotinamide derivatives and their use as therapeutic agents | |
| US20090197894A1 (en) | Nicotinamide derivatives and their use as therapeutic agents | |
| KR20110022089A (ko) | 유기 화합물 | |
| KR20090053923A (ko) | 헤테로시클릭 유기 화합물 | |
| WO2007050124A1 (en) | Fused piperidine derivatives and their uses as therapeutic agents | |
| CN101084211A (zh) | 杂环衍生物及其作为治疗剂的用途 | |
| WO2007044085A2 (en) | Heteroaryl compounds and their uses as therapeutic agents | |
| KR20060037410A (ko) | 피리다진 유도체 및 그의 치료제로서의 용도 | |
| KR20060036106A (ko) | 피리딜 유도체 및 그의 치료제로서의 용도 | |
| WO2007046868A2 (en) | Thiazolidine derivatives and their uses as therapeutic agents | |
| WO2007136746A2 (en) | Macrocyclic compounds and their uses as stearoyl-coa desaturase | |
| WO2006125180A1 (en) | Piperazine derivatives and their uses as therapeutic agents | |
| WO2006125179A1 (en) | Tricyclic compounds and their uses as therapeutic agents | |
| WO2007046867A2 (en) | Piperidine derivatives and their uses as therapeutic agents | |
| KR20120080226A (ko) | 스테아로일-ｃｏａ 탈포화화효소를 조절하는 피라졸 유도체 | |
| ITMI20130647A1 (it) | Composti con attività inibente sulle sirtuine | |
| US7390813B1 (en) | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents | |
| WO2006125181A2 (en) | Piperidine derivatives and their use as stearoyl-coa desaturase modulators | |
| WO2006125194A2 (en) | Piperazine derivatives and their uses as therapeutic agents | |
| WO2006125178A2 (en) | Tricyclic pyridazine compounds and their uses as therapeutic agents | |
| ZA200600123B (en) | Pyridyl derivatives and their use as therapeutic aPyridyl derivatives and their use as therapeutic agents gents | |
| EP2266566A2 (en) | Nicotinamide derivatives and their use as therapeutic agents |